Medacta Group Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Medacta Group (VTX:MOVE) Full Year 2022 Results

Key Financial Results

• Revenue: €437.1m (up 20% from FY 2021).
• Net income: €46.2m (down 10% from FY 2021).
• Profit margin: 11% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses.
• EPS: €2.32 (down from €2.58 in FY 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Medacta Group Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in Switzerland.

Performance of the Swiss Medical Equipment industry.

The company's shares are up 1.8% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Medacta Group you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.